|
市場調査レポート
商品コード
1360385
組織工学の世界市場の規模、シェア、成長分析：材料別、用途別 - 産業予測（2023年～2030年）Global Tissue Engineering Market Size, Share, Growth Analysis, By Material(Synthetic Material, and Biologically Derived Material), By Application(Cord blood & Cell Banking, Gynecology) - Industry Forecast 2023-2030 |
||||||
|
|||||||
| 組織工学の世界市場の規模、シェア、成長分析：材料別、用途別 - 産業予測（2023年～2030年） |
|
出版日: 2023年09月23日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
世界の組織工学の市場規模は、2022年の143億9,000万米ドルから2030年までに324億5,000万米ドルに達し、予測期間（2023年～2030年）にCAGRで10.7%の成長が予測されています。
市場は、再生医療と臓器移植の進歩により大きな成長を示しています。臓器移植の需要の増加と慢性疾患の流行に伴い、市場は拡大しています。企業は世界中で高まっている医療ニーズに対応するため、スキャフォールド、生体材料、細胞療法を含む効果的な組織工学ソリューションを開発する研究に投資しています。
促進要因
心血管疾患、整形外科疾患、臓器不全を含む慢性疾患の増加が、組織工学部門を大きく後押ししています。組織工学は、組織や臓器の再建に向けた有望な治療法を提示し、持続性の疾患に悩む人々に優れた代替の治療手段を提供します。
市場動向
世界の組織工学産業は、バイオエンジニアリングされた組織や細胞の応用に関連する安全性、有効性、倫理的配慮を含む規制の面で障害に直面しています。厳しい規制枠組みや広範囲にわたる承認手続きは、市場の進歩を妨げる可能性があり、それによって組織工学の提供や治療法へのアクセスが制限されます。
当レポートでは、世界の組織工学市場について調査分析し、市場力学と見通し、セグメント分析、企業プロファイルなどを提供しています。
目次
エグゼクティブサマリー
調査手法
親市場の分析
主な市場の考察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料の分析
- イノベーションマトリクス
- パイプライン製品の分析
- マクロ経済指標
- 主な投資の分析
- 主な成功要因
- 競合の程度
市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制情勢
- ポーターの分析
- 将来の混乱についての特別な考察
世界の組織工学市場：材料別
- 市場の概要
- 合成材料
- 生物由来材料
世界の組織工学市場：用途別
- 市場の概要
- 臍帯血・細胞バンク
- 婦人科
- がん
- 皮膚・外皮
- 歯科
- 心臓・血管
- その他
世界の組織工学の市場規模：地域別
- 市場の概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他の欧州
- アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他のアジア太平洋
- ラテンアメリカ
- ブラジル
- その他のラテンアメリカ
- 中東・アフリカ
- GCC諸国
- 南アフリカ
- その他の中東・アフリカ
競合情勢
- 上位5社の比較
- 主要企業の市場ポジショニング（2021年）
- 主な市場企業が採用した戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア（2021年）
主要企業プロファイル
- Organogenesis Holdings Inc. (US)
- Acelity L.P. Inc. (US)
- Medtronic plc (Ireland)
- Integra LifeSciences Corporation (US)
- Stryker Corporation (US)
- Zimmer Biomet Holdings, Inc. (US)
- Baxter International Inc. (US)
- Allergan plc (Ireland)
- Smith & Nephew plc (UK)
- Wright Medical Group N.V. (Netherlands)
- Cook Medical Incorporated (US)
- MiMedx Group, Inc. (US)
- Osiris Therapeutics, Inc. (US)
- Tissue Regenix Group plc (UK)
- NuVasive, Inc. (US)
- Cellular Dynamics International (US)
- Vericel Corporation (US)
- RepliCel Life Sciences Inc. (Canada)
- Organovo Holdings, Inc. (US)
- AlloSource (US)
Global Tissue Engineering Market size was valued at USD 13 Billion in 2021 and is poised to grow from USD 14.39 Billion in 2022 to USD 32.45 Billion by 2030, at a CAGR of 10.7% during the forecast period (2023-2030).
The global tissue engineering market is experiencing significant growth due to advancements in regenerative medicine and organ transplantation. This innovative field involves creating functional tissues using biocompatible materials, cells, and biochemical factors. With increasing demand for organ transplants and the rising prevalence of chronic diseases, the market is expanding. Companies are investing in research to develop effective tissue engineering solutions, including scaffolds, biomaterials, and cell therapies, to address the growing medical needs globally.
Top-down and bottom-up approaches were used to estimate and validate the size of tissue engineering and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Drivers
The uptick in chronic ailment occurrences, encompassing cardiovascular issues, orthopedic ailments, and organ insufficiencies, has significantly propelled the tissue engineering sector. Tissue engineering presents promising remedies for tissue and organ reconstruction, providing enhanced therapeutic alternatives for individuals grappling with persistent health conditions.
Restraints
Privacy and security issues emerge with the accumulation and examination of social media data, giving rise to apprehensions about data protection. The necessity for adherence to more stringent regulations and compliance protocols could present difficulties for providers of social media analytics in their task of managing and safeguarding user data.
Market Trends
The global tissue engineering industry encounters obstacles in terms of regulations encompassing the safety, effectiveness, and ethical considerations linked to the application of bioengineered tissues and cells. Stringent regulatory frameworks and extensive endorsement procedures have the potential to hinder the advancement of the market, thereby restricting the accessibility of tissue engineering offerings and treatments.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
- Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
- Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
- Global Tissue Engineering Market by Material
- Market Overview
- Synthetic Material
- and Biologically Derived Material
Global Tissue Engineering Market by Application
- Market Overview
- Cord blood & Cell Banking
- Gynecology
- Cancer
- Skin & Integumentary
- Dental
- Cardiology & Vascular
- and Others
- Global Tissue Engineering Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
- Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
- Key Company Profiles
- Organogenesis Holdings Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Acelity L.P. Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Medtronic plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Integra LifeSciences Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Stryker Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zimmer Biomet Holdings, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Baxter International Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Allergan plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Smith & Nephew plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Wright Medical Group N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cook Medical Incorporated (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- MiMedx Group, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Osiris Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Tissue Regenix Group plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- NuVasive, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cellular Dynamics International (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Vericel Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- RepliCel Life Sciences Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Organovo Holdings, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AlloSource (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
